Stochastic humoral immunity to Bacillus anthracis protective antigen: Identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization

Vaccine

Volumn 31, Issue 14, 2013, Pages 1856-1863

  Dumas, Eric K ^a,b   Nguyen, Melissa L ^a   Cox, Philip M ^a   Rodgers, Heidi ^a   Peterson, Joanne L ^a   James, Judith A ^a,b   Farris, A Darise ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

B cell epitope; Bacillus anthracis; Mice; Protective antigen; Vaccine

Indexed keywords

ANTHRAX VACCINE; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; LETHAL TOXIN ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT PROTECTIVE ANTIGEN; RECOMBINANT PROTEIN; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTHRAX; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BACILLUS ANTHRACIS; BACTERIAL IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; SEROCONVERSION; VACCINATION;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; EPITOPES, B-LYMPHOCYTE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MICE; MICE, INBRED STRAINS; PEPTIDES;

EID: 84875238547     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.040     Document Type: Article

References (41)

1. Mock M., Fouet A. Anthrax. Annu Rev Microbiol 2001, 55:647-671.
2. Jernigan J.A., Stephens D.S., Ashford D.A., Omenaca C., Topiel M.S., Galbraith M., et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001, 7(November-December (6)):933-944.
3. Bradley K.A., Mogridge J., Mourez M., Collier R.J., Young J.A. Identification of the cellular receptor for anthrax toxin. Nature 2001, 414(November (6860)):225-229.
4. Scobie H.M., Rainey G.J., Bradley K.A., Young J.A. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci USA 2003, 100(April (9)):5170-5174.
5. Klimpel K.R., Arora N., Leppla S.H. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol Microbiol 1994, 13(September (6)):1093-1100.
6. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci USA 1982, 79(May (10)):3162-3166.
7. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., et al. Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 2001, 69(May (5)):2888-2893.
8. Belton F.C., Strange R.E. Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production. Br J Exp Pathol 1954, 35(April (2)):144-152.
9. Turnbull P.C. Current status of immunization against anthrax: old vaccines may be here to stay for a while. Curr Opin Infect Dis 2000, 13(April (2)):113-120.
10. Puziss M., Wright G.G. Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man. J Bacteriol 1963, 85(January):230-236.
11. Hewetson J.F., Little S.F., Ivins B.E., Johnson W.M., Pittman P.R., Brown J.E., et al. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. Vaccine 2008, 26(August (33)):4262-4266.
12. Crowe S.R., Ash L.L., Engler R.J., Ballard J.D., Harley J.B., Farris A.D., et al. Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J Infect Dis 2010, 202(July (2)):251-260.
13. Wright J.G., Quinn C.P., Shadomy S., Messonnier N. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2010, 59(July (RR-6)):1-30.
14. Pittman P.R., Norris S.L., Barrera Oro J.G., Bedwell D., Cannon T.L., McKee K.T. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 2006, 24(April (17)):3654-3660.
15. Pittman P.R., Leitman S.F., Oro J.G., Norris S.L., Marano N.M., Ranadive M.V., et al. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin Diagn Lab Immunol 2005, 12(June (6)):713-721.
16. Crowe S.R., Garman L., Engler R.J., Farris A.D., Ballard J.D., Harley J.B., et al. Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity. Vaccine 2011, 29(May (20)):3670-3678.
17. Gorse G.J., Keitel W., Keyserling H., Taylor D.N., Lock M., Alves K., et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 2006, 24(August (33/34)):5950-5959.
18. Brown B.K., Cox J., Gillis A., VanCott T.C., Marovich M., Milazzo M., et al. Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults. PLoS ONE 2010, 5(11):e13849.
19. Tross D., Klinman D.M. Effect of CpG oligonucleotides on vaccine-induced B cell memory. J Immunol 2008, 181(October (8)):5785-5790.
20. Klinman D.M., Xie H., Little S.F., Currie D., Ivins B.E. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques. Vaccine 2004, 22(July (21/22)):2881-2886.
21. Pittman P.R., Mangiafico J.A., Rossi C.A., Cannon T.L., Gibbs P.H., Parker G.W., et al. Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine 2000, 19(September (2/3)):213-216.
22. Marano N., Plikaytis B.D., Martin S.W., Rose C., Semenova V.A., Martin S.K., et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008, 300(October (13)):1532-1543.
23. Haralambieva I.H., Ovsyannikova I.G., Dhiman N., Kennedy R.B., O'Byrne M., Pankratz V.S., et al. Common SNPs/haplotypes in IL18R1 and IL18 genes are associated with variations in humoral immunity to smallpox vaccination in Caucasians and African Americans. J Infect Dis 2011, 204(August (3)):433-441.
24. Haralambieva I.H., Ovsyannikova I.G., Umlauf B.J., Vierkant R.A., Shane Pankratz V., Jacobson R.M., et al. Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine 2011, 29(November (48)):8988-8997.
25. Haralambieva I.H., Ovsyannikova I.G., Kennedy R.B., Vierkant R.A., Pankratz V.S., Jacobson R.M., et al. Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination. Vaccine 2011, 29(October (45)):7883-7895.
26. Santiago M.L., Montano M., Benitez R., Messer R.J., Yonemoto W., Chesebro B., et al. Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 2008, 321(September (5894)):1343-1346.
27. Hohler T., Reuss E., Evers N., Dietrich E., Rittner C., Freitag C.M., et al. Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 2002, 360(September (9338)):991-995.
28. Voth D.E., Hamm E.E., Nguyen L.G., Tucker A.E., Salles I.I., Ortiz-Leduc W., et al. Bacillus anthracis oedema toxin as a cause of tissue necrosis and cell type-specific cytotoxicity. Cell Microbiol 2005, 7(August (8)):1139-1149.
29. Nguyen M.L., Crowe S.R., Kurella S., Teryzan S., Cao B., Ballard J.D., et al. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect Immun 2009, 77(January (1)):162-169.
30. Nguyen M.L., Terzyan S., Ballard J.D., James J.A., Farris A.D. The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes. Infect Immun 2009, 77(November (11)):4714-4723.
31. James J.A., Scofield R.H., Harley J.B. Basic amino acids predominate in the sequential autoantigenic determinants of the small nuclear 70K ribonucleoprotein. Scand J Immunol 1994, 39(June (6)):557-566.
32. Smith K., Crowe S.R., Garman L., Guthridge C., Muther J.J., McKee E., et al. Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Vaccine 2012, 30(June (28)):4276-4283.
33. Rivera J., Nakouzi A., Abboud N., Revskaya E., Goldman D., Collier R.J., et al. A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1. Infect Immun 2006, 74(July (7)):4149-4156.
34. Zhang J., Xu J., Li G., Dong D., Song X., Guo Q., et al. The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope. Biochem Biophys Res Commun 2006, 341(March (4)):1164-1171.
35. Abboud N., Casadevall A. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background. Clin Vaccine Immunol 2008, 15(July (7)):1115-1123.
36. Kelly-Cirino C.D., Mantis N.J. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect Immun 2009, 77(November (11)):4859-4867.
37. Kaur M., Chug H., Singh H., Chandra S., Mishra M., Sharma M., et al. Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis. Mol Immunol 2009, 46(June (10)):2107-2115.
38. Gubbins M.J., Berry J.D., Corbett C.R., Mogridge J., Yuan X.Y., Schmidt L., et al. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol Med Microbiol 2006, 47(August (3)):436-443.
39. Oscherwitz J., Yu F., Jacobs J.L., Liu T.H., Johnson P.R., Cease K.B. Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen. Infect Immun 2009, 77(August (8)):3380-3388.
40. Oscherwitz J., Yu F., Cease K.B. A synthetic peptide vaccine directed against the 2ss2-2ss3 loop of domain 2 of protective antigen protects rabbits from inhalation anthrax. J Immunol 2010, 185(September (6)):3661-3668.
41. Kwok W.W., Tan V., Gillette L., Littell C.T., Soltis M.A., LaFond R.B., et al. Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire. J Immunol 2012, 188(March (6)):2537-2544.